The wearable devices were designed to detect such conditions as cardiovascular disease, coronary artery disease and ischemic heart disease.

The eye-opening study tracked more than 1,700 patients with early-stage breast cancer.

The peptide-derived drug, M3mP6 HLPN, prevents blood clots without increasing the risk of bleeding. 

This new analysis of the ODYSSEY OUTCOMES trial includes data from more than 18,000 patients. 

The authors tracked more than 108,000 patients who suffered their first heart attack between 2009 and 2013.

The ThyrAMI-2 trial tracked 95 patients for 52 weeks of treatment. 

The risk score was found to be considerably accurate, providing results that matched the work of prior researchers.

Researchers have identified bacteria in the human gut that could reduce a person’s risk of heart disease.